Intellectus Partners LLC Buys 970 Shares of CVS Health Co. (NYSE:CVS)

Intellectus Partners LLC lifted its position in CVS Health Co. (NYSE:CVS) by 14.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 7,721 shares of the pharmacy operator’s stock after purchasing an additional 970 shares during the period. Intellectus Partners LLC’s holdings in CVS Health were worth $347,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. AMF Tjanstepension AB increased its position in shares of CVS Health by 542.2% in the fourth quarter. AMF Tjanstepension AB now owns 396,512 shares of the pharmacy operator’s stock valued at $17,799,000 after acquiring an additional 334,768 shares during the period. Davis Selected Advisers grew its stake in shares of CVS Health by 2,998.1% in the fourth quarter. Davis Selected Advisers now owns 11,385,950 shares of the pharmacy operator’s stock worth $511,115,000 after purchasing an additional 11,018,438 shares during the last quarter. Generali Investments CEE investicni spolecnost a.s. purchased a new position in CVS Health during the 4th quarter valued at about $516,000. Callan Family Office LLC bought a new position in CVS Health during the 4th quarter valued at approximately $905,000. Finally, EagleClaw Capital Managment LLC lifted its holdings in CVS Health by 3.4% in the 4th quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator’s stock worth $275,000 after buying an additional 200 shares during the period. 80.66% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other CVS Health news, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now owns 8,394 shares of the company’s stock, valued at approximately $556,941.90. The trade was a 47.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael F. Mahoney purchased 30,000 shares of the stock in a transaction dated Tuesday, February 18th. The shares were purchased at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the acquisition, the director now directly owns 39,356 shares in the company, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 0.24% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on CVS. StockNews.com raised CVS Health from a “sell” rating to a “hold” rating in a research note on Thursday, February 13th. Royal Bank of Canada dropped their target price on shares of CVS Health from $68.00 to $58.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. Barclays boosted their price target on shares of CVS Health from $71.00 to $73.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th. Truist Financial raised their price objective on shares of CVS Health from $60.00 to $76.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Finally, Piper Sandler decreased their target price on CVS Health from $72.00 to $64.00 and set an “overweight” rating for the company in a research report on Monday, November 25th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $69.83.

CVS Health Trading Up 1.7 %

Shares of NYSE CVS opened at $66.34 on Friday. The company has a market cap of $83.64 billion, a PE ratio of 18.12, a P/E/G ratio of 0.98 and a beta of 0.54. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The firm’s 50 day moving average price is $56.42 and its 200-day moving average price is $56.75. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $80.75.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. On average, equities research analysts expect that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd were paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 4.01%. The ex-dividend date of this dividend was Thursday, January 23rd. CVS Health’s dividend payout ratio is currently 72.68%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.